What drove the ALTHE.PA stock spike on 27 Jan 2026?

The rise followed heavy trading and renewed sector screening on investing platforms. No single Theraclion release explained the move; increased attention to peers and volume-driven momentum appear to be the main drivers.

What is Meyka AI's short-term forecast for ALTHE.PA stock?

Meyka AI's forecast model projects a 1-year target of **€0.90**, implying about **+3.55%** upside from the **€0.87** close. These are model projections and not guarantees.

Is ALTHE.PA stock a buy or hold given current metrics?

Meyka AI assigns ALTHE.PA a **66.93/100 (Grade B — HOLD)**. The company shows liquidity but negative earnings. This suggests caution; monitor clinical updates and cash flow before adding exposure.

What are the main risks for ALTHE.PA stock investors?

Primary risks are continued operating losses, negative book value per share, low market cap and thin trading liquidity. Regulatory or sales setbacks for Theraclion’s devices would also pressure the price.

EU Stocks

ALTHE.PA Theraclion (EURONEXT) up 22.75% on heavy volume 27 Jan 2026: model shows upside

ByDanny Kontos January 27, 2026January 27, 2026

ALTHE.PA stock jumped 22.75% to €0.87 on 27 Jan 2026 on high volume of 560,294 shares, well above the 62,263 average. That surge pushed the intraday range to €0.74–€0.93 and put the Mar 2025 year-high of €1.25 back in focus. Traders cited comparative sector screens and renewed interest in Theraclion SA’s echotherapy devices as the likely driver. We review the price move, the balance sheet signals, technicals and what our forecast model implies for short and medium term investors on EURONEXT in Europe.